# MammaPrint (70-gene signature)

Source: https://onco.cc/drugs/mammaprint/  
OnCo record `mammaprint` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A 70-gene test that tells whether an early breast cancer is genomically low or high risk, used to decide who can skip chemotherapy.

## Summary

MammaPrint is Agendia's 70-gene signature. MINDACT (n=6,693): women with high clinical but low genomic risk had 5-year distant metastasis-free survival of 94.7% without chemotherapy; 8-year update showed a small benefit of chemotherapy in women under 50. FDA-cleared (2007), NCCN-listed alongside Oncotype DX; BluePrint adds molecular subtyping. Also used to identify 'ultralow' risk tumours with indolent behaviour.

## Fields

- Kind: Treatment
- Status: established
- Last checked: 2026-09-07
- Modality: Gene-expression prognostic assay
- Mechanism: Microarray or NGS expression of 70 genes → dichotomous low/high risk.
- Approvals: US 2007: FDA 510(k) clearance for recurrence risk in early breast cancer

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/MammaPrint
- Wikipedia: https://en.wikipedia.org/wiki/MammaPrint

## Connected records

- cancers: [Ductal carcinoma in situ (DCIS)](https://onco.cc/cancers/ductal-carcinoma-in-situ/), [High-risk early HR-positive breast cancer](https://onco.cc/cancers/hr-positive-early-high-risk/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [Gene-expression prognostic assays](https://onco.cc/technologies/gene-expression-prognostic-assays/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/)
- companies: [Agendia](https://onco.cc/companies/agendia/)
- trials: [MINDACT](https://onco.cc/trials/mindact/), [TAILORx](https://onco.cc/trials/tailorx/)
- pairings: [Gene-expression assay → chemotherapy omission](https://onco.cc/pairings/genomic-assay-to-chemo-omission/)
- drugs: [Oncotype DX](https://onco.cc/drugs/oncotype-dx/), [Prosigna (PAM50)](https://onco.cc/drugs/prosigna/)
- people: [René Bernards](https://onco.cc/people/rene-bernards/)
- terms: [Enrichment and biomarker-stratified designs](https://onco.cc/terms/biomarker-stratified-design/)
- roadmaps: [Diagnostics roadmap: stains → gene panels → blood tests that decide treatment](https://onco.cc/roadmaps/diagnostics-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/mammaprint.json